Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Biopreparedness Expert Gustavo Palacios, PhD, to Join Mount Sinai, Strengthening Research Collaborations with Department of Defense
  • USA - English

Virologist Gustavo Palacios, PhD, is joining the Icahn School of Medicine at Mount Sinai from the United States Army Medical Research Institute of Infectious Diseases (USAMRIID), where he led the application and development of molecular epidemiology to advance the field of biopreparedness. Dr. Palacios will strengthen existing research collaborations between Icahn Mount Sinai and the United States Army-Department of Defense (DoD), laying a foundation for joint research initiatives to protect national and global public health.


News provided by

Mount Sinai Health System

May 06, 2021, 16:30 ET

Share this article

Share toX

Share this article

Share toX

NEW YORK, May 6, 2021 /PRNewswire-PRWeb/ -- Virologist Gustavo Palacios, PhD, is joining the Icahn School of Medicine at Mount Sinai from the United States Army Medical Research Institute of Infectious Diseases (USAMRIID), where he led the application and development of molecular epidemiology to advance the field of biopreparedness. Dr. Palacios will strengthen existing research collaborations between Icahn Mount Sinai and the United States Army-Department of Defense (DoD), laying a foundation for joint research initiatives to protect national and global public health.

As Professor of Virology at Icahn Mount Sinai, Dr. Palacios will hold appointments in Mount Sinai's Global Health and Emerging Pathogens Institute directed by Adolfo García-Sastre, PhD, Irene and Arthur M. Fishberg Professor of Medicine, and the Department of Microbiology led by Peter Palese, PhD, Horace W. Goldsmith Professor and Chair.

"I am delighted to welcome Dr. Palacios to our team as we continue to lead a national effort to understand new and emerging viruses and thwart future pandemics," said Dr. Palese. "The globe has felt the devastation of the recent pandemics, which highlight the need to invest in research and development to end the current crisis and the next one in waiting. Public, private, government, and academic efforts are crucial to create a biopreparedness system for the country and the globe. We are excited to further strengthen our ties with government researchers and scientists who share a common goal of protecting public health."

Dr. Palacios's transition to Icahn Mount Sinai is the first step to strengthen the relations and conduits between Mount Sinai and USAMRIID. Academic and government partnerships have been a priority goal of USAMRIID under the leadership of Colonel E. Darrin Cox, MD, USAMRIID Commander, to maximize the impact of DoD's research, development, and testing and evaluation investment by ensuring integration and partnership with biomedical infectious disease research centers with similar goals.

Dr. Palacios was the Founder and Director of the Center for Genomic Sciences (CGS) at USAMRIID from 2011-2019. As a Special Science Advisor to the Commander, Dr. Palacios directed a state-of-the-art genomics laboratory that houses the most advanced sequencing equipment available and led the application and the development of the field of real-time molecular epidemiology. CGS's pioneering work was demonstrated in western Africa during the 2013-2016 Ebola virus disease outbreak and during the outbreak of Zika virus in the Americas. It performed studies of viral transmission during the outbreaks of Ebola virus in the Democratic Republic of Congo (DRC) from 2018-2019, and Andes virus in South America in 2020. Dr. Palacios was the USAMRIID lead on the development program ADEPT ("Accelerated Defense against Emerging Pathogen Threats"), an integrated biopreparedness plan to respond to emerging infectious disease threats. ADEPT was endorsed by the World Health Organization as one of the six most meritorious biopreparedness proposals.

Dr. Palacios has published more than 200 peer-reviewed manuscripts including publications and covers in Cell, Science, Nature, and The New England Journal of Medicine. His current research interests include the study of transmission in person-to-person and animal-to-person routes and creating mechanisms to accelerate research and development against emerging pathogen threats.

Mount Sinai's Department of Microbiology and the Global Health and Emerging Pathogens Institute are global leaders in advancing research and understanding on emerging and re-emerging virus pathogens. They quickly reacted to the COVID-19 pandemic by dedicating research and clinical resources to mitigate it. Dr. Palacios's addition to the team further emphasizes Mount Sinai's focus on infectious diseases and biopreparedness against any serious threat that unknown viruses pose to human health. Supporting local, state, and federal needs with state-of-the-art research in this area, Mount Sinai's development of the universal influenza vaccine and a COVID-19 vaccine are just two of the many examples of its world-class research in virology and microbiology. Mount Sinai currently conducts research for several DoD agencies, including the Defense Advanced Research Projects Agency, the Defense Threat Reduction Agency, the Joint Science and Technology Office, and the Congressionally Directed Medical Research Programs.

Mount Sinai Health System is uniquely positioned to become a biosurveillance network to detect emerging pathogens and evaluate medical countermeasures and diagnostic devices to allow rapid response. During outbreaks of emerging infectious diseases, the ability to collect specimens is crucial. Clinical samples are needed to determine baseline levels of host and pathogen biomarkers, as well as for determining clinical sensitivity and specificity values to inform diagnostic test development and refinement. The outbreak of SARS-CoV-2, the virus that causes COVID-19, during 2020 and West Nile virus in 1999 demonstrate the huge impact of travel and movement of goods in the introduction of emerging pathogens through New York City. The unique collaboration between Mount Sinai, the U.S. Army, and DoD is paramount to prepare for future events.

For more than 50 years, USAMRIID has provided leading-edge medical capabilities to deter and defend against current and emerging biological threat agents. The Institute is the only laboratory in the Department of Defense equipped to safely study highly hazardous viruses requiring maximum containment at biosafety level 4. Research conducted at USAMRIID leads to medical solutions—vaccines, drugs, diagnostics, information, and training programs—that benefit both military personnel and civilians. Over the years, USAMRIID has shown itself to be uniquely suited to answer the nation's call, and 2020—marked by the COVID-19 pandemic—was no exception.

"USAMRIID looks forward to strengthening our relationship with Mount Sinai," said Colonel Cox. "Academic relationships help us maximize the impact of DoD's research, development, and testing and evaluation investment. Through integration and collaboration, we can share USAMRIID's capabilities while leveraging those of other public and private biomedical research centers with similar goals and interests."

"To efficiently and effectively counter an epidemic caused by a known or unknown pathogen, deliberate and advanced research expertise, planning, and development are crucial for a rapid and strategic response. Our government and industry partners enable the accelerated development of medical countermeasures and global defense. The collaboration between USAMRIID and Mount Sinai will enhance the world's capabilities for an integrated response to the current and future global pandemics," said Dennis S. Charney, MD, Anne and Joel Ehrenkranz Dean of Icahn Mount Sinai and President for Academic Affairs at Mount Sinai Health System.

About the Mount Sinai Health System
The Mount Sinai Health System is New York City's largest academic medical system, encompassing eight hospitals, a leading medical school, and a vast network of ambulatory practices throughout the greater New York region. Mount Sinai is a national and international source of unrivaled education, translational research and discovery, and collaborative clinical leadership ensuring that we deliver the highest quality care—from prevention to treatment of the most serious and complex human diseases. The Health System includes more than 7,200 physicians and features a robust and continually expanding network of multispecialty services, including more than 400 ambulatory practice locations throughout the five boroughs of New York City, Westchester, and Long Island. The Mount Sinai Hospital is ranked No. 14 on U.S. News & World Report's "Honor Roll" of the Top 20 Best Hospitals in the country and the Icahn School of Medicine as one of the Top 20 Best Medical Schools in country. Mount Sinai Health System hospitals are consistently ranked regionally by specialty and our physicians in the top 1 percent of all physicians nationally by U.S. News & World Report.
For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Twitter and YouTube.

Media Contact

Lucia Lee, Mount Sinai Health System, 212-241-9200, [email protected]

SOURCE Mount Sinai Health System

Related Links

https://www.mountsinai.org

Modal title

Gustavo Palacios, PhD
Gustavo Palacios, PhD
Gustavo Palacios, PhD

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.